Healthcare Industry News: EEG
News Release - June 12, 2007
LinkMed: SACS Medical is Granted FDA Clearance
STOCKHOLM, Sweden--(HSMN NewsFeed)--LinkMed's (STO:LMED) portfolio company SACS Medical has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for sales of its systems in the U.S."FDA clearance is a stamp of quality that will facilitate us in our search for an industrial partner for SACS Medical," says Ingemar Lagerlof, CEO, LinkMed.
The clearance is for SACS Medical's system for medical signal handling, which can handle EEG and EMG signals, among others. The system is used by specialist clinics to diagnose, monitor and treat patients spread over a large geographical area from one centralized location. 510(k) clearance is a prerequisite for sales of this category of medtech products in the U.S.
LinkMed's ownership stake in SACS Medical is 43 percent.
LinkMed, in collaboration with innovators develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical technology. The LinkMed share is listed on the Stockholm Stock Exchange and the company's largest owners are FastPartner, Koncentra Holding, Mannerson Fastigheter and the founder Ingemar Lagerlof. See linkmed.se for more information.
Source: LinkMed
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!